AUTHORS
Nisha Joseph, MD, Jiaqi Fang, MBBS, MPH2, Amol Dhamane, BPharm3, Christian Gentili4, Gabriela Hernandez Rivera5, Yu-Hsuan Shih6
AFFILIATIONS
1 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
2 Bristol Myers Squibb, Princeton, New Jersey, United States
3 Bristol Myers Squibb, Princeton, New Jersey, United States
4 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
5 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
6 Bristol Myers Squibb, Princeton, New Jersey, United States
ABSTRACT
Introduction:
Multiple myeloma (MM) is the second most common hematological malignancy in adults, with incidence rates continuing to rise globally. Bispecific T-cell–engaging antibodies (BsAbs) have emerged as a significant advancement in treating relapsed/refractory MM (RRMM), demonstrating deep and durable responses in heavily pretreated patients. However, their immunosuppressive mechanisms, including T-cell dysregulation and immunoglobulin suppression, confer a substantial risk of infection and significant healthcare resource utilization (HCRU). Real-world data characterizing the magnitude of these burdens are limited. This study describes HCRU and infection burden among patients with RRMM treated with BsAbs using a claims database in the United States (US).
Methods:
This was a retrospective cohort study using the IQVIA PharMetrics Plus® Enhanced Closed Claims database. Eligible patients had a diagnosis of MM from January 1, 2017 through September 30, 2025, received at least one prior line of therapy, received at least one BsAb, had ≥6 months of continuous enrollment prior to the index date (defined as the start date of the first BsAb), and had at least 1 month of follow-up post index date. Patients with a clinical trial drug prior to the index date were excluded. Outcomes were assessed from index date through end of available follow-up and included: all-cause hospitalizations (hospitalizations due to any cause), emergency room (ER) visits, and intensive care unit (ICU) admissions; intravenous immunoglobulin (IVIG) use and frequency (median cycles per patient per year [PPPY]); documented infections by type; Infection-related hospitalizations were examined using two definitions: 1) a broader definition (relevant ICD codes on any diagnosis field in the inpatient claim) and, 2) a stricter definition using relevant ICD codes on primary/secondary diagnosis fields only. Descriptive statistics were used to summarize all outcomes.
Results:
A total of 355 patients with RRMM treated with BsAbs were included (teclistamab [n=310, 87.3%]; talquetamab [n=37, 10.4%], and elranatamab [n=8, 2.3%]). Median follow-up time from index was 7.5 months (interquartile range [IQR]: 3.7, 15.1). Median age was 70 years (range 25–85); 55.5% were male. The majority of patients had high comorbidity burden, with 87.3% having a Charlson Comorbidity Score ≥3, and 86.2% with documented renal insufficiency or impairment.
83.7% of patients were hospitalized during follow-up after initiating BsAbs, with an average of 3.7 hospitalizations per year (standard deviation [SD]=4.2) and a median length of stay of 8.0 days (range 0–44.0). 46.5% of patients had at least one ER visit, averaging 1.9 visits per year (SD=3.9). Additionally, 34.6% of patients required ICU-level care, with an average of 1.2 ICU admissions per year (SD=2.6).
IVIG was administered to 221 patients (62.3%) during follow-up, with a median of 6 cycles PPPY. Despite high IVIG use, documented infections were observed in 246 patients (69.3%). Respiratory tract infections (excluding PJP and COVID-19) were the most common (55.2% including pneumonia [39.2%]), followed by bacterial infections (38.3%), and viral infections [excluding COVID-19] (13.8%). Infection-related hospitalizations were identified in 154 patients (43.4%) using the broader definition and 130 patients (36.6%) using the stricter definition.
Conclusions:
In this real-world US claims analysis, patients with RRMM receiving BsAbs experienced substantial HCRU and high IVIG utilization. Notably, infection-related hospitalizations remained frequent despite high IVIG use. These findings underscore the clinical and economic burden of infectious complications among patients treated with BsAbs and highlight the need for more effective infection management strategies or alternative treatment options particularly in areas with limited healthcare resources.
DISCLOSURES
Nisha Joseph, MD: Janssen - Honoraria; Bristol Myers Squibb - Honoraria; Legend Biotech - Honoraria; Regeneron Pharmaceuticals, Inc. - Research Funding; Novartis - Research Funding; Bristol Myers Squibb - Research Funding; Janssen - Research Funding; Janssen - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)